Navigation Links
Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
Date:5/28/2009

or kidney problems; gastrointestinal (GI) perforations (the development of a hole in the stomach, small intestine, or large intestine); and severe blistering skin reactions including cases similar to Stevens-Johnson syndrome. Patients taking Tarceva plus gemcitabine were more likely to experience bleeding and clotting problems such as heart attack or stroke. Eye irritation and damage to the cornea have been reported in patients taking Tarceva. Women should avoid becoming pregnant and avoid breastfeeding while taking Tarceva. Patients should call their doctor right away if they have these signs or symptoms: new or worsening skin rash; serious or ongoing diarrhea, nausea, loss of appetite, vomiting, or stomach pain; new or worsening shortness of breath or cough; fever; eye irritation. Rash and diarrhea were the most common side effects associated with Tarceva in the non-small cell lung cancer clinical study. Fatigue, rash, nausea, loss of appetite, and diarrhea were the most common side effects associated with Tarceva plus gemcitabine therapy in the pancreatic cancer clinical study.

For full prescribing information, please call 1-877-TARCEVA or visit http://www.tarceva.com.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology and Oncology. The company's aim is to discover and manufacture products tha
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.; OSI Pharmaceuticals; Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinsons Disease
2. The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation
3. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
4. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
5. National Medical Interpreter Certification Testing Enters Pilot Phase
6. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
7. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
10. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
11. Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... GenHart Software, LLC, a rising player in ... small businesses operate as efficiently and cost effectively as possible, with a belief that ... their first year of operation – and the Charleston business community is taking notice. ...
(Date:8/30/2015)... , ... August 31, 2015 , ... Avid collector Andrew ... the Doors Shrine Auditorium concert posters. This hand colored artwork is one of the ... in Los Angles. Hawley states, "When the doors played the Shrine, the band ...
(Date:8/30/2015)... DE (PRWEB) , ... August 31, 2015 , ... ... exhibitor at the AHCA/NCAL 66th Annual Convention & Expo October 5th & 6th ... and organizations together, the AHCA/NCAL convention brings industry professionals from all over the ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... across platforms and devices, today announced it is a Silver Sponsor of the ... at Sky City Convention Centre in Auckland, NZ. Throughout the event, AvePoint will ...
(Date:8/30/2015)... ... ... Natural Rest contains a unique mixture of vitamins and herbs that are ... to improve mood disorders and anxiety. Like all other Creative Medical Health products, Natural ... regenerative medicine conducted by Dr. Amit Patel of the University of Utah, one of ...
Breaking Medicine News(10 mins):Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 3Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2
... woman who comes to a health care centre does increase ... partners, a new study confirms. The study, led by ... at St. Michael,s Hospital, represents a major reversal of thinking ... or intimate partner violence. Until now, the research and ...
... around 2 billion dollars a year on remediation at ... used for groundwater monitoring. Yet according to Rolf Halden, ... information gathered is often of limited value. Under ... Department of Defense, Halden, assistant director at the Institute,s ...
... -- The sooner rehabilitation begins after knee replacement, the ... In the study, published March 7 in the ... than 150 patients who began rehabilitation within 24 hours ... of patients who began rehabilitation 48 to 72 hours ...
... , FRIDAY, March 4 (HealthDay News) -- In what experts ... have for the first time turned human embryonic stem cells ... of brain cell that,s lost to Alzheimer,s disease. The ... cholinergic" (BFC) neurons, is key to the progression of Alzheimer,s. ...
... Walter and Eliza Hall Institute have identified the key ... response. The finding could have wide-ranging repercussions for ... and change how the efficacy of newly developed drugs ... Erika Cretney, Dr Axel Kallies and Dr Stephen Nutt ...
... Sledding is the most common cause of injury among winter ... list of the top five injury-causing winter activities. "More ... States due to sledding. More than 30 percent are head ... specialist at Gottlieb Memorial Hospital in Melrose Park, Ill., part ...
Cached Medicine News:Health News:Universal screening programs can uncover abuse, study finds 2Health News:Monitoring waste in groundwater (without all the waste) 2Health News:Scientists Use Stem Cells, Skin Cells to Create Brain Cells Lost to Alzheimer's 2Health News:Scientists Use Stem Cells, Skin Cells to Create Brain Cells Lost to Alzheimer's 3Health News:Scientists Use Stem Cells, Skin Cells to Create Brain Cells Lost to Alzheimer's 4Health News:Newly identified cell population key to immune response 2
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., a ... cancer, today announced the filing of a registration statement ... Commission (SEC) relating to a proposed initial public offering ... be offered and the price range for the offering ... its common stock under the symbol "CTMX" on the ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2
... Dec. 14, 2010 Samplify Systems, Inc., a ... the ultrasound market, is pleased to announce that ... has won Electronic Design Magazine,s Best ... category.  Details of Samplify,s AutoFocus™ beamforming technology currently ...
... 14, 2010 Pacira Pharmaceuticals, Inc. ... the New Drug Application (NDA) for EXPAREL™, a long-acting ... filing by the U.S. Food and Drug Administration (FDA). ... the initial indication of postsurgical analgesia by local administration. ...
Cached Medicine Technology:Samplify's AutoFocus™ Beamforming Technology Awarded Electronic Design's 'Best of 2010' 2
Cold light source single outlet....
... The 4150S is a state ... halogen light source with an ... standard coupler to connect optical ... source distinguishes itself from all ...
The 9300XSP is the brightest light source available. Visualize more clearly, see color more accurately, and work more effectively. Luxtecs xenon lighting delivers bright, white light that is as close...
The Carl Zeiss Head-worn Loupes L and LC are the ideal solution if a low magnification suffices for your work and you want to keep your hands free to perform the task at hand....
Medicine Products: